Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide

Clinica Chimica Acta

Volumn 413, Issue 5-6, 2012, Pages 544-547

  Klersy, Catherine ^a   d'Eril, Gian Vico Melzi ^b   Barassi, Alessandra ^b   Palladini, Giovanni ^c   Comelli, Mario ^c   Moratti, Remigio ^c   Albertini, Riccardo ^c   Merlini, Giampaolo ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Biological variability; Monitoring; Nested ANOVA; Normalizing transformation; NT proBNP; Reference change value

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ANALYTICAL PARAMETERS; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DATA PROCESSING; FEMALE; HEART FAILURE; HUMAN; LABORATORY TEST; LOGNORMAL APPROACH; MALE; NESTED ANALYSIS OF VARIANCE; PATIENT MONITORING; PEPTIDE ANALYSIS; PRIORITY JOURNAL; REFERENCE CHANGE VALUE; STATISTICAL ANALYSIS;

FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REFERENCE VALUES;

EID: 84856212591     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.11.012     Document Type: Article

References (25)

1. Bettencourt P., Azevedo A., Pimenta J., Friöes F., Ferreira S., Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004, 110:2168-2174.
2. Doust J.A., Pietrzak E., Dobson A., Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005, 330:625-633.
3. Latini R., Masson S., Wong M., et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006, 119(70):e23-e30.
4. Masson S., latini R., Anand I.S., et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 2008, 52:997-1003.
5. Miller W.L., Hartman K.A., Grill D.E., Burnett J.C., Jaffe A.S. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 2009, 55:78-84.
6. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) levels improve outcome. Lancet 2000, 335:1126-1130.
7. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Hear J 2009, 158:422-430.
8. Clerico A., Fontana M., Ripoli A., Emdin M. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv Clin Chem 2009, 48:163-179.
9. Porapakkham P., Porapakkham P., Zimmet H. B-type natriuretic peptide-guided heart failure therapy. A meta-analysis. Arch Intern Med 2010, 170:507-514.
10. O'Donoghue M., Barunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels?. Nat Rev Cardiol 2010, 7:13-20.
11. Fraser C.G., Harris E.K. Generation and application of data of biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989, 27:409-437.
12. Fraser C.G. Biological variation: from principles to practice 2001, AACC Press, Washington, 151pp.
13. Wu A.H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006, 152:828-834.
14. Bruins S., Fokkema M.R., Romer J.W.P., et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004, 40:2052-2058.
15. Schou M., Gustafsson F., Nielsen P.H., Madsen L.H., Kjaer A., Hildebrandt P.R. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007, 9:68-74.
16. Tuxen M.K., Sölétormos G., Petersen P.H., Dombernowsky P. Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) Based on analytical imprecision and biological variation in the monitoring of ovarian cancer. Clin Chem Lab Med 2001, 39:531-538.
17. von Eyben F.E., Petersen P.H., Blaabjerg O., Madsen E.L. Analytical quality specifications for serum lactate dehydrogenase isoenzyme 1 based on clinical goals. Clin Chem Lab Med 1999, 7:553-561.
18. Fokkema M.R., Herrmann Z., Muskiet F.A.J., Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006, 52:1602-1603.
19. Petersen P.H., Blaabjerg O., Andersen M., Jorgensen L.G.M., Schousboe K., Jensen E. Graphical interpretation of confidence curves in rankit plots. Clin Chem Lab Med 2004, 42:715-724.
20. D'Agostino R.B., Balanger A., D'Agostino R.B. A suggestion for using powerful and informative test of normality. Am Stat 1990, 44:316-321.
21. Clerico A., Zucchelli G.C., Pilo A., Passino C., Emdin M. Clinical relevance of biological variation: the lesson of brain peptide (BNP) and NT-proBNP assay. Clin Chem Lab Med 2006, 44:366-378.
22. Wu A.H.B., Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004, 6:355-358.
23. O'Hanlon R., O'Shea P., Ledwidge M., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007, 13:50-55.
24. Ricós C., Iglesias N., García-Lario J.V., et al. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007, 44:343-352.
25. Fraser C.G. Reference change values. Clin Chem Lab Med Sep. 30 2011, 10.1515/CCLM.2011.733.